A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
← catalyst calendarNCT06616766 · readout in 574 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
201estimated
Sites
8
Countries
South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-02 | actual | When the study began enrolling |
| Primary completion | 2028-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-29 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Solid Tumor
Intervention
- Drug: YH42946
Primary outcomes
what the primary-completion date above is the date OFTreatment Emergent Adverse Events(TEAE)s
measured Through study completion, during the first 21 days of DLT evaluation period.
Objective Response Rate (ORR)
measured Through dose expansion part completion, approximately 12 months
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed